Roivant Sciences

Yahoo Finance • 8 days ago

Top Growth Companies With Strong Insider Ownership For November 2025

As the U.S. stock market experiences a significant upswing, with major indexes like the Nasdaq and S&P 500 posting notable gains, investors are keenly observing growth companies that exhibit strong insider ownership. In such a buoyant mark... Full story

Yahoo Finance • 24 days ago

Roivant Sciences GAAP EPS of -$0.17 beats by $0.16, revenue of $1.57M misses by $5.35M

* Roivant Sciences press release [https://seekingalpha.com/pr/20300059-roivant-reports-financial-results-for-the-second-quarter-ended-september-30-2025-and-provides] (ROIV [https://seekingalpha.com/symbol/ROIV]): Q2 GAAP EPS of -$0.17 be... Full story

Yahoo Finance • 24 days ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. B... Full story

Yahoo Finance • 27 days ago

Pre-Market Earnings Report for November 10, 2025 : B, B, TSN, ROIV, KSPI, TSEM, MNDY, CART, STWD, RDNT, BEKE, BXSL

The following companies are expected to report earnings prior to market open on 11/10/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Barrick Mining Corporation (B)is reporting for the quarter ending Se... Full story

Yahoo Finance • 27 days ago

Roivant Sciences Q2 2026 Earnings Preview

* Roivant Sciences (ROIV [https://seekingalpha.com/symbol/ROIV]) is scheduled to announce Q2 earnings results on Monday, November 10th, before market open. * The consensus EPS Estimate is -$0.30 [https://seekingalpha.com/symbol/ROIV/ea... Full story

Yahoo Finance • last month

argenx SE beats top-line and bottom-line estimates; reaffirms FY25 outlook

* argenx SE press release [https://seekingalpha.com/pr/20285593-argenx-reports-third-quarter-2025-financial-results-and-provides-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q3 GAAP EPS of $5.18 beats by $0.83. * Rev... Full story

Yahoo Finance • last month

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, Nov... Full story

Yahoo Finance • last month

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financi... Full story

Yahoo Finance • last month

Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV)

​Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the Best Growth Stocks Under $25 to Buy Right Now. Wall Street has a mixed opinion on Roivant Sciences Ltd. (NASDAQ:ROIV) since the company announced positive results from its Phase 3 VALOR st... Full story

Yahoo Finance • 2 months ago

Roivant Sciences files shelf registration for potential securities offerings

* Roivant Sciences (NASDAQ:ROIV [https://seekingalpha.com/symbol/ROIV]) may offer common shares, preference shares, debt securities, warrants, and units from time to time. * The offerings may be made by the company or selling securityh... Full story

Yahoo Finance • 2 months ago

Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The corporate Bitcoin treasury playbook just got another high-profile convert as Vivek Ramaswamy’s Strive (NASDAQ: ASST) on Sept. 22 anno... Full story

Yahoo Finance • 2 months ago

Monday 9/22 Insider Buying Report: HAIN, ROIV

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th... Full story

Yahoo Finance • 3 months ago

Stocks Settle Mixed on Hawkish Fed Chair Powell Comments

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Wednesday closed down -0.10%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.... Full story

Yahoo Finance • 3 months ago

Stocks Tread Water as FOMC Decision Nears

The S&P 500 Index ($SPX) (SPY) today is down -0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.62%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.42%.  September E-mini S&P futures (ESU25) are down -0.09%, and September E-... Full story

Yahoo Finance • 3 months ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscl... Full story

Yahoo Finance • 3 months ago

Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock

Vivek Ramaswamy sold more than $22 million worth of Roivant Sciences stock in three separate transactions last week, according to a filing with the U.S. Securities and Exchange Commission. Ramaswamy founded Roivant Sciences in 2014 and ser... Full story

Yahoo Finance • 3 months ago

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List. This is Roivant’s firs... Full story

Yahoo Finance • 3 months ago

Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat

In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now. Roivant Sciences Ltd. is one of them. Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company focused on accelerating the... Full story

Yahoo Finance • 3 months ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no suffi... Full story

Yahoo Finance • 3 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story